肾脏病与透析肾移植杂志 ›› 2021, Vol. 30 ›› Issue (3): 252-257.DOI: 10.3969/j.issn.1006298X.2021.03.013
• • 上一篇 下一篇
出版日期:
发布日期:
Online:
Published:
摘要： 近年来轻链型淀粉样变性的治疗手段日益丰富。抗CD38单克隆抗体已成功应用于浆细胞疾病和多发性骨髓瘤的治疗,系列研究报道了其对轻链型淀粉样变性的疗效,本文拟简述该药治疗系统性轻链型淀粉样变性的临床应用进展。
关键词: 抗CD38单克隆抗体,系统性轻链型淀粉样变性,疗效,不良反应
Abstract: Recently, with the development of new drugs, treatment of light chain amyloidosis has been enriched. As an important therapeutic target, antiCD38 monoclonal antibodies has been developed for plasma cell diseases and has been successful in multiple myeloma. Since then, antiCD38 monoclonal antibodies have been used for the treatment of light chain amyloidosis, and series of research results have been published, showing encouraging efficacy and safety. This article will review research progress of antiCD38 monoclonal antibodies in treatment of light chain amyloidosis.
Key words: anti-CD38 monoclonal antibody, light chain amyloidosis, efficacy, adverse events
黄湘华, 刘志红. 抗CD38单克隆抗体治疗系统性轻链型淀粉样变性[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 252-257.
HUANG Xianghua, LIU Zhihong. Anti-CD38 monoclonal antibody-based therapy for systemic light chain amyloidosis[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2021, 30(3): 252-257.
0 / / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: http://www.njcndt.com/CN/10.3969/j.issn.1006298X.2021.03.013
http://www.njcndt.com/CN/Y2021/V30/I3/252
